BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22127114)

  • 1. BRCA and beyond: a genome-first approach to familial breast cancer risk assessment.
    Trainer AH; Thompson E; James PA
    Discov Med; 2011 Nov; 12(66):433-43. PubMed ID: 22127114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
    Balleine RL; Provan PJ; Pupo GM; Pathmanathan N; Cummings M; Farshid G; Salisbury EL; Bilous AM; Byth K; ; Mann GJ
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1082-94. PubMed ID: 20815029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18. Genetics of breast cancer.
    Irving M; Elmslie F; Berg J
    Int J Clin Pract; 2002 Nov; 56(9):677-82. PubMed ID: 12469982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic susceptibility for breast cancer: how many more genes to be found?
    Oldenburg RA; Meijers-Heijboer H; Cornelisse CJ; Devilee P
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):125-49. PubMed ID: 17498966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerous high-risk epithelial lesions in familial breast cancer.
    Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
    Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
    Fu R; Harris EL; Helfand M; Nelson HD
    Stat Med; 2007 Apr; 26(8):1775-87. PubMed ID: 17243094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
    Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
    Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models of genetic susceptibility to breast cancer.
    Antoniou AC; Easton DF
    Oncogene; 2006 Sep; 25(43):5898-905. PubMed ID: 16998504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?].
    Bonadona V; Lasset C
    Bull Cancer; 2003 Jul; 90(7):587-94. PubMed ID: 12957799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A breast cancer prediction model incorporating familial and personal risk factors.
    Tyrer J; Duffy SW; Cuzick J
    Stat Med; 2004 Apr; 23(7):1111-30. PubMed ID: 15057881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk assessment for familial occurrence of breast cancer].
    Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
    Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
    Loman N
    Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.